Fig. 1.

PFKM expression informs poor survival in bevacizumab-treated glioblastoma. (A) High glycolytic rate profile informs poor outcome of patients receiving bevacizumab in the AVAglio dataset. (B) PFKM and ALDOC expression levels informed survival of GBM patients under bevacizumab therapy. Data presented as median survival difference. (C) High PFKM but not PFKL and PFKP expression levels inform the survival of GBM patients in BELOB trial. (D) Immunohistochemistry shows elevated PFKM expression in WHO grade IV glioma (GBM) tumor periphery (n = 23). (E) Darmanis’s single-cell RNA-seq dataset shows PFKM but not PFKP or PFKL expression is elevated in invading neoplastic cells.

Significance is determined by log-rank test (A, C) or t test (D, E) and where applicable, data are shown as mean ± SEM (*P < .05, **P < .01, ***P < .001).